Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 262,503 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 262,503 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $0.38, for a total transaction of $99,751.14. Following the transaction, the insider owned 361,229 shares in the company, valued at $137,267.02. The trade was a 42.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total transaction of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total transaction of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Trading Up 8.0%

Shares of HOWL stock opened at $0.39 on Friday. The firm has a market capitalization of $19.16 million, a PE ratio of -0.32 and a beta of 0.29. The firm has a fifty day simple moving average of $0.67 and a two-hundred day simple moving average of $0.72. Werewolf Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently made changes to their positions in the company. Regal Investment Advisors LLC grew its stake in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.